Ekvira Fine-Chem Profile
Key Indicators
- Authorised Capital ₹ 1.10 M
as on 10-12-2024
- Paid Up Capital ₹ 1.10 M
as on 10-12-2024
- Company Age 31 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.85 M
as on 10-12-2024
- Revenue 51.84%
(FY 2022)
- Profit 56.18%
(FY 2022)
- Ebitda 51.62%
(FY 2022)
- Net Worth 23.89%
(FY 2022)
- Total Assets 12.71%
(FY 2022)
About Ekvira Fine-Chem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.10 M and a paid-up capital of Rs 1.10 M.
The company currently has active open charges totaling ₹2.85 M.
Radheshyam Tawani, Nandkishor Patil, Vaibhav Nandkishor, and One other member serve as directors at the Company.
- CIN/LLPIN
U24130MH1993PTC073063
- Company No.
073063
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jul 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ekvira Fine-Chem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyesh Tawani  | Director | 01-Oct-2020 | Current |
| Radheshyam Tawani | Director | 22-Jul-1993 | Current |
| Nandkishor Patil | Director | 22-Jul-1993 | Current |
| Vaibhav Nandkishor | Director | 01-Oct-2020 | Current |
Financial Performance of Ekvira Fine-Chem.
Ekvira Fine-Chem Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 51.84% increase. The company also saw a substantial improvement in profitability, with a 56.18% increase in profit. The company's net worth Soared by an impressive increase of 23.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ekvira Fine-Chem?
In 2020, Ekvira Fine-Chem had a promoter holding of 93.18% and a public holding of 6.82%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ramdev Chemi Pharma Private LimitedActive 18 years 11 monthsRadheshyam Tawani, Nandkishor Patil and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Allahabad Bank Creation Date: 27 Aug 2003 | ₹2.85 M | Open |
How Many Employees Work at Ekvira Fine-Chem?
Ekvira Fine-Chem has a workforce of 6 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ekvira Fine-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ekvira Fine-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
